Notably, the research also demonstrates that TZP can synergize with standard chemotherapeutic agents, such as oxaliplatin, 5-fluorouracil (5-FU), and SN-38, potentially enhancing efficacy while reducing treatment toxicity
*In a 72-week study of adults without diabetes, average weight loss was 15.0% (34 lbs) for 5mg, 19.5% (44 lbs) for 10mg, 20.9% (48 lbs) for 15 mg, and 3.1 (7 lbs) for placebo
It has been studied in preclinical and clinical research for its effects on glycemic regulation, insulin sensitivity, appetite signaling, and metabolic function
The eligibility criteria for Tirzepatide are a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related health condition
20mg/mL concentration chart The 20mg/mL concentration is twice as strong